Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trial

In a bold attempt to stop the progress of some cases of Alzheimer’s disease, a group of researchers is trying something new — injecting a protective gene into patients’ brains.…

New research helps explain the progression of Alzheimer’s disease and predicts its severity — ScienceDaily

Alzheimer’s disease has always had its puzzles and contradictions. For Pacific Northwest National Laboratory (PNNL) researcher Vladislav Petyuk, whose research on the progressive, age-related disease spans over a decade, some…

Alzheimer’s Drug May Benefit Some Patients, New Data Shows

Dr. Thambisetty said the two deaths add to questions about lecanemab’s safety issues “in real world clinical practice where patients are likely to be sicker and have multiple other medical…

COVID-19 amplifies damage to the central nervous system in Alzheimer’s disease

In a recent study published in the journal Annals of Diagnostic Pathology, researchers in the United States evaluated the impact of coronavirus disease 2019 (COVID-19) on central nervous system (CNS)…

Alzheimer’s drug slows progression of cognitive decline in clinical trial, drugmakers say

CNN  —  A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The…

New antibody shows therapeutic effects in mice with Alzheimer’s disease — ScienceDaily

A newly developed agonistic antibody reduced the amyloid pathology in mice with Alzheimer’s disease, signaling its promise as a potential treatment for the disease, according to a team of researchers…

When Alzheimer’s degrades cells that cross hemispheres, visual memory suffers — ScienceDaily

A new MIT study finds that Alzheimer’s disease disrupts at least one form of visual memory by degrading a newly identified circuit that connects the vision processing centers of each…

Could a computer diagnose Alzheimer’s disease and dementia? — ScienceDaily

It takes a lot of time — and money — to diagnose Alzheimer’s disease. After running lengthy in-person neuropsychological exams, clinicians have to transcribe, review, and analyze every response in…

Gene discovery may explain why more women get Alzheimer’s disease

The gene, O6-Methylguanine-DNA-methyltransferase, or MGMT, plays an important role in how the body repairs damage to DNA in both men and women. But researchers did not find an association between…

Trial of New Alzheimer’s Drug Reports Disappointing Results

A closely watched clinical trial of a potential Alzheimer’s drug failed to prevent or slow cognitive decline, another disappointment in the long and challenging effort to find solutions for the…